Positron emission tomography for urological tumours.

Area of Science:

• Uro-oncology
• Diagnostic Imaging
• Nuclear Medicine

Background:

• Positron emission tomography (PET) is an advanced imaging technique with potential applications in various urological cancers.
• Current diagnostic modalities like computed tomography (CT) and magnetic resonance imaging (MRI) have limitations in staging and recurrence detection for certain urological malignancies.

Purpose of the Study:

• To evaluate the effectiveness of positron emission tomography (PET) in the diagnosis, staging, and recurrence detection of urological tumours.
• To compare PET imaging with conventional methods like CT and MRI for different types of urological cancers.

Main Methods:

• Review of existing studies on PET imaging in testicular, prostate, renal, and bladder cancers.
• Analysis of PET's sensitivity and specificity in detecting primary tumours, residual masses, and metastatic disease.
• Comparison of PET performance against CT and MRI for local staging and detection of bone metastases.

Main Results:

• PET demonstrates high sensitivity and specificity for detecting recurrent testicular cancer and staging renal cancer.
• PET imaging offers improved local staging for renal and bladder cancers compared to CT and MRI.
• PET's role in prostate cancer imaging is variable, with limitations in differentiating tumour from hypertrophy and detecting bone metastases compared to bone scans.

Conclusions:

• Positron emission tomography (PET) is a valuable tool, particularly for testicular and renal cancers, in detecting recurrence and aiding in staging.
• Further research is needed to establish the full potential of PET in prostate and bladder cancer management.
• Development of novel PET tracers beyond fluorodeoxyglucose (FDG) is expanding its utility in urological oncology.